FAST NEWS: Wuxi Bio Dives after Major Stakeholder Sells Shares
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Tuesday that Biologics Holdings, one of its substantial shareholders controlled by its Chairman Li Ge, sold 56…
FAST NEWS: WuXi Biologics Announces $300 Million Share Buyback
The latest: Contract drugs services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Monday its board of directors has approved a plan to buy back up to $300 million of the…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
WuXi AppTec Revenue Soars as Changing Government Policies Bring Headaches
The CXO giant announced it expects to post record-high revenue in the first quarter of 2022 Key takeaways: WuXi AppTec said it expects year-on-year revenue growth of 65% to 68%…
FAST NEWS: Drug Discovery Business Helps Viva Biotech Swing Back to Profit
The latest: Viva Biotech Holdings (1873.HK) released a positive profit forecast, saying it posted a net profit of 300 million yuan ($48.2 million) or more last year, reversing a loss…
